niclosamide has been researched along with Carcinoma, Hepatocellular in 5 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide (NIC) is an anthelmintic agent repurposed as a potent anticancer agent." | 5.56 | Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways. ( Abdel-Rahman, N; Eissa, LA; El-Karef, A; El-Sherbiny, IM; Yahia, S; Zeyada, MS, 2020) |
| " Oral administration of NEN to mice significantly slowed growth of genetically induced liver tumors and patient-derived xenografts, whereas niclosamide did not, coinciding with the observed greater bioavailability of NEN compared with niclosamide." | 5.46 | Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. ( Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B, 2017) |
| "Niclosamide (NIC) is an anthelmintic agent repurposed as a potent anticancer agent." | 1.56 | Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways. ( Abdel-Rahman, N; Eissa, LA; El-Karef, A; El-Sherbiny, IM; Yahia, S; Zeyada, MS, 2020) |
| " Oral administration of NEN to mice significantly slowed growth of genetically induced liver tumors and patient-derived xenografts, whereas niclosamide did not, coinciding with the observed greater bioavailability of NEN compared with niclosamide." | 1.46 | Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. ( Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B, 2017) |
| "Hepatocellular carcinoma was then developed in the transgenic zebrafish." | 1.42 | Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis. ( Choi, JH; Chung, YY; Jung, IH; Lim, GL; Park, SW; Park, YN, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zeyada, MS | 1 |
| Abdel-Rahman, N | 1 |
| El-Karef, A | 1 |
| Yahia, S | 1 |
| El-Sherbiny, IM | 1 |
| Eissa, LA | 1 |
| Chien, MH | 1 |
| Ho, YC | 1 |
| Yang, SF | 1 |
| Yang, YC | 1 |
| Lai, SY | 1 |
| Chen, WS | 1 |
| Chen, MJ | 1 |
| Yeh, CB | 1 |
| Jung, IH | 1 |
| Choi, JH | 1 |
| Chung, YY | 1 |
| Lim, GL | 1 |
| Park, YN | 1 |
| Park, SW | 1 |
| Weng, S | 1 |
| Zhou, L | 1 |
| Deng, Q | 1 |
| Wang, J | 1 |
| Yu, Y | 1 |
| Zhu, J | 1 |
| Yuan, Y | 1 |
| Chen, B | 1 |
| Wei, W | 1 |
| Ma, L | 1 |
| Yang, B | 1 |
| Gill, RM | 1 |
| Chua, MS | 1 |
| Butte, AJ | 1 |
| So, S | 1 |
5 other studies available for niclosamide and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Carriers; Liver Neopl | 2020 |
Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression.
Topics: Administration, Oral; Anthelmintics; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dow | 2018 |
Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis.
Topics: Aminopyridines; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Cyclic S-Oxides | 2015 |
Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells.
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Anthelmintics; Apoptosis; Carc | 2016 |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ce | 2017 |